About this Journal Submit a Manuscript Table of Contents
Journal of Biomarkers
Volume 2013 (2013), Article ID 538765, 15 pages
http://dx.doi.org/10.1155/2013/538765
Review Article

Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach

1Center for Shock, Trauma and Anesthesiology Research (STAR) and the Department of Anesthesiology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
2Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA
3Department of Biochemistry, Dr. Ram Manohar Lohia Avadh University, Faizabad 224001, India

Received 28 August 2012; Accepted 2 February 2013

Academic Editor: Maria Dusinska

Copyright © 2013 Alok Kumar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Amyotrophic lateral sclerosis (ALS) is one of the most common motor neurodegenerative disorders, primarily affecting upper and lower motor neurons in the brain, brainstem, and spinal cord, resulting in paralysis due to muscle weakness and atrophy. The majority of patients die within 3–5 years of symptom onset as a consequence of respiratory failure. Due to relatively fast progression of the disease, early diagnosis is essential. Metabolomics offer a unique opportunity to understand the spatiotemporal metabolic crosstalks through the assessment of body fluids and tissue. So far, one of the most challenging issues related to ALS is to understand the variation of metabolites in body fluids and CNS with the progression of disease. In this paper we will review the changes in metabolic profile in response to disease progression condition and also see the therapeutic implication of various drugs in ALS patients.